The present invention discloses a novel film coating composition of polyvinyl alcohol (PVA) in combination with sugar, and a plasticizer or a combination of plasticizers resulting in a composition which is non tacky and easily dispersible in water at high solids content. The coating compositions help in achieving higher spray rates, disperse in less solvent i.e water, and helps in reduction of coating process time. Further the resultant film which when coated onto substrates exhibits good adhesion and provides smooth surface to substrates.

Methods of improving visual endpoints related to retina-associated disease with CCR3 modulating agents are provided. An example of such an endpoint is visual acuity. Retina-associated diseases upon which visual acuity and other visual endpoints may be improved include retinopathy of prematurity, age-related macular degeneration, central retinal vein occlusion, and diabetic retinopathy.

There is provided an alkali metal salt of 4-chloro-N-[2-[(4-chlorophenyl)methyl]-3-oxo-1, 2,4-thiadiazol-5-yl]benzamide and formulations thereof. This salt finds particular utility in the treatment or prevention of a disorder or condition ameliorated by the activation of AMPK.

The present invention relates to a controlled release formulation comprising the active compounds tesofensine and a beta blocker, such as metoprolol or carvedilol, or a pharmaceutically acceptable salt thereof. The invention further relates to use of the controlled release formulation in a method of treatment of diabetes, obesity, or an obesity associated disorder.

In exemplary embodiments, the disclosure provides a Colesevelam Colon Specific Drug Delivery System for use in treatment of, for example insufficient glycemic control in a patient.

The present invention relates to a method of treating a tauopathy in a subject, a method of improving cognitive ability in a subject suffering from cognitive impairment associated with a tauopathy, a method of reducing tau aggregates and neurofibrillary tangles. The method comprises administering an agent which promotes phosphorylation of tau at threonine in the sequence SSPGSPGTPGSRSR of the tau; and/or introduces a phosphomimetic of a phosphorylated tau, wherein the phosphorylated tau is tau that has been phosphorylated at threonine in the sequence SSPGSPGTPGSRSR of the tau.

The present disclosure relates to bilayer tablets comprising a second layer comprising a β-lactam compound or a pharmaceutically acceptable salt thereof; and a first layer comprising probenecid or a pharmaceutically acceptable salt thereof. The present disclosure also relates to methods of treating or preventing a disease using the bilayer tablets.

The present invention relates to solid dosage forms comprising coatings based on natural ingredients, such as naturally-occuring esterified and non-esterified polyuronic acids, optionally in combination with stabilising lipophilic component(s) (e.g. surfactant(s)) and/or other stabilising components. The inventors have made the surprising discovery that polysaccharide-based coatings can be stabilised, and often imparted with gastric resistant properties, through the inclusion of particular additives and/or additional layers. In particular, polyuronic acid-containing coatings may be stabilised and rendered more robust through the inclusion of a lipophilic component (e.g. surfactant), an esterified polyuronic acid, and/or the deployment of an additional coating layer containing stabilising agents that affect the disintegration and/or dissolution of the polyuronic acid. The polyuronic acid-containing coatings of the invention can exhibit retarded disintegration at gastric pH whilst remaining readily disintegratable at higher pHs. As such, the coatings of the invention provide inter alia promising candidates for enteric coatings.

The present invention relates to pharmaceutical oral dosage forms releasing compounds in specific parts of the small intestine of a subject, wherein said compounds stimulate enteroendocrine cells in the subject's jejunum and lower small intestine to release one or more enterokines. The present invention also relates to a method of producing such pharmaceutical oral dosage forms. The pharmaceutical oral dosage forms of the invention are particularly for use in the treatment and prevention of metabolic conditions or diseases, osteoporosis, malabsorption conditions, neurodegenerative diseases, conditions of impaired gastro-intestinal function and cardiovascular diseases.

The present disclosure provides dosage form coating compositions and suspensions, coatings, coated dosage forms, and methods of making and using the same. The dosage form coating compositions can include a hydroxypropyl cellulose and a carboxymethylcellulose. The hydroxypropyl cellulose can be present in an amount by weight of at least 18.0% and at most 25.0%. The hydroxypropyl cellulose can be present in a ration of at least 1:1.4 and at most 1.4:1 relative to the carboxymethyl cellulose. The coated dosage forms can have an improved slip force, an improve swallowability as represented by an incline transit distance, or an improved gloss.